Kymera Therapeutics (KYMR) PT Raised to $144 at BofA Securities

September 14, 2026 5:43 AM

BofA Securities analyst Geoff Meacham raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $144.00 (from $123.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found